This company listing is no longer active
VIVO Cannabis Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-28.1%
Tasa de crecimiento de los beneficios
-5.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | 25.4% |
| Rentabilidad financiera | -127.5% |
| Margen neto | -190.5% |
| Última actualización de beneficios | 31 Dec 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero VIVO Cannabis. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 22 | 25 | -48 | 16 | 0 |
| 30 Sep 22 | 25 | -108 | 16 | 0 |
| 30 Jun 22 | 25 | -105 | 16 | 0 |
| 31 Mar 22 | 26 | -70 | 16 | 0 |
| 31 Dec 21 | 25 | -70 | 16 | 0 |
| 30 Sep 21 | 24 | -45 | 18 | 0 |
| 30 Jun 21 | 26 | -49 | 18 | 0 |
| 31 Mar 21 | 30 | -48 | 19 | 0 |
| 31 Dec 20 | 33 | -56 | 21 | 0 |
| 30 Sep 20 | 35 | -33 | 20 | 0 |
| 30 Jun 20 | 33 | -38 | 23 | 0 |
| 31 Mar 20 | 28 | -47 | 24 | 0 |
| 31 Dec 19 | 25 | -31 | 24 | 0 |
| 30 Sep 19 | 22 | -27 | 29 | 0 |
| 30 Jun 19 | 18 | -26 | 28 | 0 |
| 31 Mar 19 | 14 | -13 | 26 | 0 |
| 31 Dec 18 | 10 | -25 | 27 | 0 |
| 30 Sep 18 | 4 | -28 | 24 | 0 |
| 30 Jun 18 | 2 | -23 | 21 | 0 |
| 31 Mar 18 | 1 | -33 | 20 | 0 |
| 31 Dec 17 | 1 | -29 | 15 | 0 |
| 30 Sep 17 | 1 | -21 | 10 | 0 |
| 30 Jun 17 | 1 | -19 | 8 | 0 |
| 31 Mar 17 | 1 | -9 | 6 | 0 |
| 31 Dec 16 | 1 | -6 | 5 | 0 |
| 30 Sep 16 | 0 | -4 | 3 | 0 |
Ingresos de calidad: 23Q is currently unprofitable.
Margen de beneficios creciente: 23Q is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 23Q is unprofitable, and losses have increased over the past 5 years at a rate of 28.1% per year.
Acelerando crecimiento: Unable to compare 23Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 23Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.4%).
Rentabilidad financiera
Alta ROE: 23Q has a negative Return on Equity (-127.5%), as it is currently unprofitable.